2024-516801-22-00进行中（未招募）3 期
SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 141
- 试验地点
- 11
- 主要终点
- DFS: Invasive disease-free survival (DFS) - time from the second registration (randomization) to local, regional, or distant recurrence, new invasive primary, or death due to any cause. The STEEP definition of invasive disease-free survival (IDFS) is used, although it is referred to here by the more common acronym DFS. Survival times are censored at time of last follow-up for individuals who did not have any event meeting the above definition.
研究概览
简要总结
To determine the effect of chemotherapy in patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®. In patients with 1-3 positive nodes, and hormone receptor (HR)-positive, HER2-negative breast cancer with RS ≤ 25 treated with endocrine therapy we will test whether the difference in disease-free survival for patients treated with chemotherapy compared to no chemotherapy depends directly on the magnitude of RS. If benefit depends on the RS score, the trial will determine the optimal cutpoint for recommending chemotherapy or not.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Step 1 Registration (Oncotype DX® Screening): Patients must have a histologically confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2 status. Estrogen and progesterone receptor positivity must be assessed according to ASCO/CAP guidelines as either ER or PR ≥ 1% positive nuclear staining. HER-2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using IHC, ISH or both. HER-2 equivocal is not eligible.
- •Step 1 Registration (Oncotype DX® Screening): Patients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agents.
- •Step 1 Registration (Oncotype DX® Screening): Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registration.
- •Step 1 Registration (Oncotype DX® Screening: Patients must not be pregnant or nursing due to the possibility of harm to a fetus or nursing infant from this treatment regimen.
- •Step 1 Registration (Oncotype DX® Screening: No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.
- •Step 1 Registration (Oncotype DX® Screening: The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/
- •Step 1 Registration (Oncotype DX® Screening: Patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
- •Step 2 Registration (Randomization): Recurrence score (RS) by Oncotype DX® must be ≤
- •Step 2 Registration (Randomization): Step 2 Registration must take place within 84 days after definitive surgery. Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomization.
- •Step 2 Registration (Randomization): Patients randomized to either arm may also co-enroll in Phase III trials that compare local therapies, or compare systemic therapies (such as chemotherapy, if randomized to Arm 1 of S1007).
- •Step 2 Registration (Randomization): The Quality of Life and Economic Substudy is permanently closed to accrual effective 12/1/
- •Patients at U.S. INSTITUTIONS only.
- •Step 1 Registration (Oncotype DX® Screening): Patients with multifocal, multicentric and synchronous bilateral breast cancers are allowed. Patients will have undergone axillary staging by sentinel node biopsy or axillary lymph nodes dissection (ALND). Patients must have at least one, but no more than three known positive lymph nodes (pN1a, pN1b or pN1c). Patients with micrometastases as the only nodal involvement (pN1mi) are not eligible. Patients with positive sentinel node are not required to undergo full axillary lymph node dissection. This is at the discretion of the treating physician. Axillary node evaluation is to be performed per the standard of care at each insititution.
- •Step 2 Registration (Randomization): All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. For all patients the appropriate consent form for this registration is the Step 2 Consent Form.
- •Step 1 Registration (Oncotype DX® Screening): Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation). Patients must have clear margins from both invasive breast cancer and DCIS (as per local institutional guidelines). LCIS at the margins is allowed.
- •Step 1 Registration (Oncotype DX® Screening): Registration of patients who have not yet undergone Oncotype DX® screening must occur no later than 56 days after definitive surgery. If the Oncotype DX® Breast Cancer Assay has not been performed, patients must be willing to submit tissue samples for testing to determine the Recurrence Score value. A representative block or unstained sections from the representative block are sent directly to Genomic Health for Oncotype DX® Breast Cancer Assay which will be performed according to the standard commercial process. If the Oncotype DX® Recurrence Score is already known and is 25 or less, the patient must be registered to Step 2 immediately following Step 1 registration. If the Oncotype DX® Recurrence Score is already known and is greater than 25, the patient is ineligible.
- •Step 1 Registration (Oncotype DX® Screening): Patients must be females ≥ 18 years of age. As the Oncotype DX ® Recurrence Score has not been validated in men with breast cancer, men are not eligible for this study.
- •Step 1 Registration (Oncotype DX® Screening): Patients must have a complete history and physical examination within 28 days prior to registration.
- •Step 1 Registration (Oncotype DX® Screening): Patients must have a performance status of 0-2 by Zubrod criteria.
- •Step 1 Registration (Oncotype DX® Screening): Patients must be able to receive taxane and/or anthracycline based chemotherapy.
- •Step 1 Registration (Oncotype DX® Screening): Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registration.
排除标准
- •Patients must not have inflammatory breast cancer and must not have metastatic disease.
- •Patients with a prior diagnosis of contralateral DCIS are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation. Prior partial breast irradiation, including brachytherapy, is not allowed. Patients with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received radiation to that breast are not eligible.
- •Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to registration.
- •Patients must not require chronic treatment with systemic steroids (inhaled steroids are allowed) or other immunosuppressive agents.
- •Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registration.
- •Patients must not be pregnant or nursing due to the possibility of harm to a fetus or nursing infant from this treatment regimen. Women of reproductive potential must have agreed to use an effective contraceptive method. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.
- •No other prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.
- •Step 2 Registration must take place within 84 days after definitive surgery. Patients must not have begun chemotherapy or endocrine therapy for their breast cancer prior to randomization.
结局指标
主要结局
DFS: Invasive disease-free survival (DFS) - time from the second registration (randomization) to local, regional, or distant recurrence, new invasive primary, or death due to any cause. The STEEP definition of invasive disease-free survival (IDFS) is used, although it is referred to here by the more common acronym DFS. Survival times are censored at time of last follow-up for individuals who did not have any event meeting the above definition.
DFS: Invasive disease-free survival (DFS) - time from the second registration (randomization) to local, regional, or distant recurrence, new invasive primary, or death due to any cause. The STEEP definition of invasive disease-free survival (IDFS) is used, although it is referred to here by the more common acronym DFS. Survival times are censored at time of last follow-up for individuals who did not have any event meeting the above definition.
次要结局
- OS: Overall survival (OS) - time from the second registration (randomization) to death due to any cause. Survival times are censored at time of last follow-up for individuals who are not known to have died.
- DDFS: Distant disease-free survival (DDFS) - time from second registration to distant recurrence, new invasive primary, or death due to any cause. Patients who have local or regional recurrence are continued to be followed for a distant event or death. Survival times are censored at time of last follow-up for individuals who are not known to have died and have not had a distant recurrence or new primary.
- LDFI: Local-regional disease-free interval (LDFI) - time from second registration to local/regional recurrence. 3 Patients who have distant recurrence or a new primary or who die without recurrence are censored at time of this event. The analysis of this endpoint must account for informative censoring using a competing risk framework. Survival times are also censored at time of last follow-up for individuals who are not known to have died and have had a recurrence or new primary.
- Toxicity: Toxicities using standard NCI-CTCAE criteria (CTCAE Version 4.0).
研究者
Head of Clinical Operations
Scientific
Cancer Trials Ireland
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
3 期
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.” RXPONDER2024-515368-29-00Fundacion Grupo Espanol De Investigacion En Cancer De Mama792
招募中
2 期
Herombopag Treated T-DM1 Induced Platelet ReductionThrombocytopeniaNCT07257809Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University56
招募中
2 期
The p53 breast cancer trialbreast cancer2024-515135-29-00Helse Bergen HF63
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
已完成
3 期
Clinically node negative breast cancer patients undergoing breast conserving therapy: Sentinel lymph node procedure versus follow-up. A Dutch randomized controlled multicentre trial.sentinel lymph node metastasessentinel lymph nodes1000629110006295breast cancerNL-OMON54499Medisch Universitair Ziekenhuis Maastricht1,730